Literature DB >> 7911833

Influence of corticosteroid pulse therapy on the serum levels of soluble interleukin 2 receptor, interleukin 6 and interleukin 8 in patients with rheumatoid arthritis.

H R van den Brink1, M J van Wijk, R G Geertzen, J W Bijlsma.   

Abstract

OBJECTIVE: To investigate the influence of corticosteroid pulse (CP) therapy on soluble interleukin 2 receptor (sIL-2R), interleukin 6 (IL-6) and IL-8 levels in patients with active rheumatoid arthritis (RA).
METHODS: Twenty-five patients with active RA were studied before and after treatment with intravenous CP therapy. In 12 patients lymphocyte subsets were also assessed.
RESULTS: All patients showed a significant decrease in clinical disease activity variables after 4 to 8 weeks of CP therapy. Baseline levels of sIL-2R were higher among patients with active RA than healthy controls; after CP therapy, sIL-2R levels decreased significantly, but not as much as the erythrocyte sedimentation rate or C-reactive protein. In most cases baseline levels of both IL-6 (n = 23) and IL-8 (n = 17) could be measured and both decreased significantly after CP therapy. Cortisol levels were suppressed shortly after CP therapy but had returned to pretreatment values at 4 weeks. After CP therapy there was a temporary increase in the number of HLA-DR positive cells and a decrease in the number of CD3 positive cells, while the CD4/CD8 ratio and IL-2 receptor (CD25) positive cells remained unchanged.
CONCLUSION: High dose corticosteroids influence serum levels of sIL-2R, IL-6 and IL-8 in patients with active RA.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7911833

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  8 in total

1.  Low circulating soluble interleukin 2 receptor level predicts rapid response in patients with refractory rheumatoid arthritis treated with infliximab.

Authors:  A Kuuliala; R Nissinen; H Kautiainen; H Repo; M Leirisalo-Repo
Journal:  Ann Rheum Dis       Date:  2005-06-07       Impact factor: 19.103

2.  Monocyte activation in rheumatoid arthritis (RA): increased integrin, Fc gamma and complement receptor expression and the effect of glucocorticoids.

Authors:  I Torsteinsdóttir; N G Arvidson; R Hällgren; L Håkansson
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

3.  The immune suppressive effect of dexamethasone in rheumatoid arthritis is accompanied by upregulation of interleukin 10 and by differential changes in interferon gamma and interleukin 4 production.

Authors:  C M Verhoef; J A van Roon; M E Vianen; F P Lafeber; J W Bijlsma
Journal:  Ann Rheum Dis       Date:  1999-01       Impact factor: 19.103

4.  Relationship between Serum Level of Interleukin-2 in Patients with Systemic Lupus Erythematosus and Disease Activity in Comparison with Control Group.

Authors:  Sima Sedighi; Mehrdad Aghaei; Sara Musavi; Mahin Nomali
Journal:  J Clin Diagn Res       Date:  2014-07-20

5.  Endogenous glucocorticoids modulate neutrophil migration and synovial P-selectin but not neutrophil phagocytic or oxidative function in experimental arthritis.

Authors:  M Leech; P Hutchinson; S R Holdsworth; E F Morand
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

6.  Serum soluble interleukin-2 receptor levels in rheumatoid arthritis: effect of methotrexate, sulphasalazine and hydroxychloroquine therapy.

Authors:  F Salaffi; M Carotti; C Cervini
Journal:  Clin Rheumatol       Date:  1995-07       Impact factor: 2.980

7.  Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures.

Authors:  Joel M Kremer; David A Lawrence; Robert Hamilton; Iain B McInnes
Journal:  RMD Open       Date:  2016-06-09

8.  Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.

Authors:  Jose Luis Rodriguez-Garcia; Gines Sanchez-Nievas; Juan Arevalo-Serrano; Cristina Garcia-Gomez; Jose Maria Jimenez-Vizuete; Elisa Martinez-Alfaro
Journal:  Rheumatology (Oxford)       Date:  2021-01-05       Impact factor: 7.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.